Immunovia is preparing to market its IMMray PanCan-d for self-pay patients at high risk of pancreatic cancer (PC) in Q418, after preparatory activities were pushed back slightly from mid-2017 to 2018. To achieve reimbursement, a prospective trial in this population is being run and if positive, the test could be reimbursed in 2020. Immunovia is pursuing other groups ie patients with new-onset T2 diabetes aged 50+ and those with early gastric symptoms. Our revised valuation is SEK3.6bn as we now include early gastric symptoms. Autoimmune diseases represent upside.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs